162112-37-0
162112-37-0 結構式
基本信息
N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide
1H-Pyrazole-4-carboxamide, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-2-thiazolyl]-
N-(3-Hydroxypropyl)-5-methyl-1-[-4-[3-(trifluoromethyl)phenyl)]-2-thiazolyl]-1H-pyrazole-4-carboxamide
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-110086 | RWJ 50271 | 162112-37-0 | 1 mg | 900元 |
| 2026/06/05 | HY-110086 | RWJ 50271 RWJ 50271 | 162112-37-0 | 5mg | 1800元 |
| 2026/06/05 | HY-110086 | RWJ 50271 RWJ 50271 | 162112-37-0 | 10mM * 1mLin DMSO | 1980元 |
常見問題列表
IC50: 5.0 μM (LFA-1/ICAM-1, HL60 cells)
RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 inhibits both human and murine NK activity (IC
50
=5.0 μM) in an LFA-1/ICAM-1-dependent natural killer [NK] cytotoxicity assay.
RWJ 50271 does not inhibit Mac-1/ICAM-1, E-selectidsialyl Lewis X or VLA-4/VCAM-1-mediated cell adhesion up to 20 μM concentrations.
RWJ 50271 does not alter the LFA-1 expression levels on HL60 cells.
RWJ 50271 inhibits adhesion of peripheral blood lymphocytes to plastic immobilized SICAM-1.
RWJ 50271 does not exhibit any toxic activity up to 100 μM concentrations.
RWJ 50271 (50 mg/kg; p.o.) is effective in animal model of inflammation.
| Animal Model: | Mice, the delayed-type hypersensitivity [DTH] reaction model |
| Dosage: | 50 mg/kg |
| Administration: | Oral administration |
| Result: | Significantly reduced foot pad swelling (>50%) 48 h after the challenge. |